Patients: 22 obese patients without diabetes, metabolic syndrome, or steatohepatitis were randomized to cFMT (n = 11) or placebo (n = 11).Primary outcome(s): safety through week 26.Secondary outcome(s): changes in gut microbiome profile, bile acid profile, SCFA, change in obesity markers including GLP1, and leptin. The gene discussed is LEP; the disease is obesity disorder.